SCHEMBL30869709

SCHEMBL30869709

Cc1cc2c(cc1Br)Oc1cc(Br)cnc1N2

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 3/20 0.32
▸ BCHE P06276 1/20 0.30
▸ CES1 P23141 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869747 1.00 AHR (0.32) AHRBCHECES1SMN1; SMN2
SCHEMBL30869696 0.79 MMP12 (0.38) AHRSMN1; SMN2
SCHEMBL30869620 0.79 AHR (0.38) AHRSMN1; SMN2
SCHEMBL30869424 0.79 AHR (0.38) AHRSMN1; SMN2
SCHEMBL30869575 0.78 AHR (0.42) AHRCES1
SCHEMBL30869584 0.78 AHR (0.42) AHRCES1
SCHEMBL30869514 0.64 ALDH1A1 (0.33) —
SCHEMBL27325923 0.64 VRK1 (0.50) —
SCHEMBL6466406 0.63 AHR (0.68) AHRBCHECES1
SCHEMBL38661474 0.63 ALOX5 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 — — US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 — — EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 AHR 4553/4885BCHE 4450/4885CES1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback